# WaKING: Wnt and checKpoint INhibition in Gastric Cancer

> **NCT04166721** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 52 (estimated)

## Conditions studied

- Metastatic Esophageal Cancer
- Metastatic Gastric Cancer

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04166721
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-11
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04166721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04166721, "WaKING: Wnt and checKpoint INhibition in Gastric Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04166721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*